Table 2.
Clinical characteristics at baseline of the whole cohort and in patients with and without a thrombo‐embolic endpoint
| Predictor | Whole cohort | No TE | TE | |||
|---|---|---|---|---|---|---|
| Total | Mean (SD)/n (%) | Total | Mean (SD)/n (%) | Total | Mean (SD)/n (%) | |
| Age | 4817 | 48.99 (16.40) | 4645 | 48.74 (16.39) | 172 | 55.73 (15.40) |
| LA | 4627 | 43.97 (7.74) | 4460 | 43.82 (7.68) | 167 | 47.83 (8.37) |
| MWT | 4768 | 19.44 (5.15) | 4599 | 19.42 (5.18) | 169 | 20.05 (4.16) |
| FS | 4358 | 0.41 (0.10) | 4198 | 0.41 (0.10) | 160 | 0.40 (0.09) |
| LVOT max | 4168 | 31.95 (40.94) | 4023 | 31.85 (40.96) | 145 | 34.72 (40.46) |
| Female | 4820 | 1740 (36.10) | 4648 | 1666 (35.84) | 172 | 74 (43.02) |
| Prior TE | 4821 | 80 (1.66) | 4649 | 71 (1.53) | 172 | 9 (5.23) |
| AF | 4815 | 600 (12.46) | 4643 | 552 (11.89) | 172 | 48 (27.91) |
| VKA | 4818 | 443 (9.20) | 4646 | 410 (8.82) | 172 | 33 (19.19) |
| NYHA II | 4615 | 1584 (34.32) | 4450 | 1519 (34.13) | 165 | 65 (39.29) |
| NYHA III, IV | 4615 | 494 (10.70) | 4450 | 456 (10.24) | 165 | 38 (23.03) |
| Vascular disease | 3588 | 89 (2.48) | 3438 | 79 (22.98) | 150 | 10 (6.67) |
| Hypertension | 4712 | 1414 (30.00) | 4541 | 1354 (29.82) | 171 | 60 (35.09) |
| Diabetes | 4020 | 293 (7.29) | 3868 | 279 (7.21) | 152 | 14 (9.21) |
Breakdown of AF in the whole cohort: paroxysmal 314, persistent 102, permanent 181, not specified 3.
FS, fractional shortening; LA, left atrial size, LVOT max, maximum LV outflow gradient; MWT, aximal wall thickness; SD, standard deviation; TE, thrombo‐embolic event; VKA, vitamin K antagonist.